Interview with Peter Smith
Co-Founder, President and CEO of Remix Therapeutics
Last year, Peter gave us insight into the emerging technologies that fascinate him in the RNA field. He shared what we can expect from Remix in the upcoming years and why he chose to join the ranks of RNA Leaders.
Peter, can you tell us a little bit about yourself and your focus within RNA?
I’m the Co-Founder and CEO of a company called Remix Therapeutics. We're based in Massachusetts, in the USA. Our approach is discovering and developing selective small molecules that can modulate RNP processing, and that's allowing us to tackle a number of so-called undruggable disease drivers with this new approach that we're taking.
Which emerging technologies within the field excite you most currently?
Good question. There's a lot of new technologies. I'm particularly inspired by small molecules. That's our focus at Remix. I think there's huge potential there to discover novel modalities, novel mechanisms with small molecules to impact RNA in the convenience of oral dosing and tissue distribution. I think a number of areas where we can think about the right approach will be a small molecule to impact RNA biology
Why did you decide to be a part of RNA Leaders for a launch event in Basel?
It looked like a great agenda, you know, quite diverse topics across the RNA landscape. So, a good way to stay abreast of kind of the latest developments in the field. Also, the ability to interact with human beings in person again was particularly attractive.
And which areas of the RNA leader's agenda this year interested you most in one?
Well, we're only a third of the way through the conference, so we're still looking forward to some of the things that are coming up. But I think just seeing a spectrum of small companies, novel approaches that they're taking and how that's being fed into the larger companies and even hearing from some of the bigger pharma companies and how they are thinking about RNA broadly and then where their interests lie have been. It's been really enlightening to hear those aspects.
What can we expect to be hearing from Remix Therapeutics over the next months and years? Any milestones coming up? What's next for you?
We're excited to present tomorrow at the conference. Really pleased to share updates to our story there. And then as the year advances, we’ll continue to start to inform the community of the work that we're doing. We were really excited about some of the breakthroughs that we've made on our small molecule approaches, and we think it's going to be important for us to share those so that the field can be aware of them and start to be inspired by those learnings that we've had.
“I think a number of areas where we can think about the right approach will be a small molecule to impact RNA biology.”
What can we expect to be hearing from Remix Therapeutics over the next months and years? Any milestones coming up? What's next for you?
We're excited to present tomorrow at the conference. Really pleased to share updates to our story there. And then as the year advances, we’ll continue to start to inform the community of the work that we're doing. We were really excited about some of the breakthroughs that we've made on our small molecule approaches, and we think it's going to be important for us to share those so that the field can be aware of them and start to be inspired by those learnings that we've had.
Join us for the second year of RNA Leaders Europe in 2023. You’ll have the chance to learn about the latest, discovery, clinical, manufacturing and commercially viable developments across mRNA, RNAi, and ASOs therapeutics and next-generation RNA Vaccines. Tickets on sale
LSX is the Life Science eXecutive partnering community.
We connect biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.
contact | privacy policy | good conduct policy | anti-slavery policy | anti-money laundering & financial crime policy | diversity & inclusion policy | terms & conditions
© 2022 all rights reserved by LSX Ltd
